Stock Events

Notable Labs 

$1.27
1
+$0+0.4% Today

Statistics

Day High
-
Day Low
-
52W High
5.27
52W Low
0.13
Volume
370,234
Avg. Volume
68,964
Mkt Cap
11.41M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
Next
-5.6
-3.74
-1.87
-0.01
Expected EPS
-0.37
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NTBL. It's not an investment recommendation.

Analyst Ratings

9$Average Price Target
The highest estimate is $9.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

About

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
Show more...
CEO
Dror Harats
Employees
41
Country
IL
ISIN
IL0012002452

Listings